124 related articles for article (PubMed ID: 16165154)
1. Crystal structures of a high-affinity macrocyclic peptide mimetic in complex with the Grb2 SH2 domain.
Phan J; Shi ZD; Burke TR; Waugh DS
J Mol Biol; 2005 Oct; 353(1):104-15. PubMed ID: 16165154
[TBL] [Abstract][Full Text] [Related]
2. Crystal structures of the SH2 domain of Grb2: highlight on the binding of a new high-affinity inhibitor.
Nioche P; Liu WQ; Broutin I; Charbonnier F; Latreille MT; Vidal M; Roques B; Garbay C; Ducruix A
J Mol Biol; 2002 Feb; 315(5):1167-77. PubMed ID: 11827484
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a novel nonphosphorylated pentapeptide motif displaying high affinity for Grb2-SH2 domain by the utilization of 3'-substituted tyrosine derivatives.
Song YL; Peach ML; Roller PP; Qiu S; Wang S; Long YQ
J Med Chem; 2006 Mar; 49(5):1585-96. PubMed ID: 16509576
[TBL] [Abstract][Full Text] [Related]
4. Utilization of a beta-aminophosphotyrosyl mimetic in the design and synthesis of macrocyclic Grb2 SH2 domain-binding peptides.
Lee K; Zhang M; Liu H; Yang D; Burke TR
J Med Chem; 2003 Jun; 46(13):2621-30. PubMed ID: 12801226
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for a non-phosphorus-containing cyclic peptide binding to Grb2-SH2 domain with high affinity.
Li P; Zhang M; Peach ML; Zhang X; Liu H; Nicklaus M; Yang D; Roller PP
Biochem Biophys Res Commun; 2003 Aug; 307(4):1038-44. PubMed ID: 12878216
[TBL] [Abstract][Full Text] [Related]
6. Solution structure of the Grb2 SH2 domain complexed with a high-affinity inhibitor.
Ogura K; Shiga T; Yokochi M; Yuzawa S; Burke TR; Inagaki F
J Biomol NMR; 2008 Nov; 42(3):197-207. PubMed ID: 18830565
[TBL] [Abstract][Full Text] [Related]
7. Macrocyclization in the design of Grb2 SH2 domain-binding ligands exhibiting high potency in whole-cell systems.
Wei CQ; Gao Y; Lee K; Guo R; Li B; Zhang M; Yang D; Burke TR
J Med Chem; 2003 Jan; 46(2):244-54. PubMed ID: 12519063
[TBL] [Abstract][Full Text] [Related]
8. Binding affinity difference induced by the stereochemistry of the sulfoxide bridge of the cyclic peptide inhibitors of Grb2-SH2 domain: NMR studies for the structural origin.
Shi YH; Song YL; Lin DH; Tan J; Roller PP; Li Q; Long YQ; Song GQ
Biochem Biophys Res Commun; 2005 May; 330(4):1254-61. PubMed ID: 15823578
[TBL] [Abstract][Full Text] [Related]
9. Macrocyclization in the design of non-phosphorus-containing Grb2 SH2 domain-binding ligands.
Shi ZD; Wei CQ; Lee K; Liu H; Zhang M; Araki T; Roberts LR; Worthy KM; Fisher RJ; Neel BG; Kelley JA; Yang D; Burke TR
J Med Chem; 2004 Apr; 47(8):2166-9. PubMed ID: 15056012
[TBL] [Abstract][Full Text] [Related]
10. Utilization of 3'-carboxy-containing tyrosine derivatives as a new class of phosphotyrosyl mimetics in the preparation of novel non-phosphorylated cyclic peptide inhibitors of the Grb2-SH2 domain.
Song YL; Tan J; Luo XM; Long YQ
Org Biomol Chem; 2006 Feb; 4(4):659-66. PubMed ID: 16467940
[TBL] [Abstract][Full Text] [Related]
11. Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands.
Yao ZJ; King CR; Cao T; Kelley J; Milne GW; Voigt JH; Burke TR
J Med Chem; 1999 Jan; 42(1):25-35. PubMed ID: 9888830
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of a C-terminally biotinylated macrocyclic peptide mimetic exhibiting high Grb2 SH2 domain-binding affinity.
Shi ZD; Liu H; Zhang M; Worthy KM; Bindu L; Yang D; Fisher RJ; Burke TR
Bioorg Med Chem; 2005 Jul; 13(13):4200-8. PubMed ID: 15893931
[TBL] [Abstract][Full Text] [Related]
13. Solution structure and dynamics of G1TE, a nonphosphorylated cyclic peptide inhibitor for the Grb2 SH2 domain.
Lou YC; Lung FD; Pai MT; Tzeng SR; Wei SY; Roller PP; Cheng JW
Arch Biochem Biophys; 1999 Dec; 372(2):309-14. PubMed ID: 10600169
[TBL] [Abstract][Full Text] [Related]
14. Surface plasmon resonance thermodynamic and kinetic analysis as a strategic tool in drug design. Distinct ways for phosphopeptides to plug into Src- and Grb2 SH2 domains.
de Mol NJ; Dekker FJ; Broutin I; Fischer MJ; Liskamp RM
J Med Chem; 2005 Feb; 48(3):753-63. PubMed ID: 15689159
[TBL] [Abstract][Full Text] [Related]
15. Interaction of the non-phosphorylated peptide G7-18NATE with Grb7-SH2 domain requires phosphate for enhanced affinity and specificity.
Gunzburg MJ; Ambaye ND; Del Borgo MP; Pero SC; Krag DN; Wilce MC; Wilce JA
J Mol Recognit; 2012 Jan; 25(1):57-67. PubMed ID: 22213451
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for the high affinity of amino-aromatic SH2 phosphopeptide ligands.
Rahuel J; García-Echeverría C; Furet P; Strauss A; Caravatti G; Fretz H; Schoepfer J; Gay B
J Mol Biol; 1998 Jun; 279(4):1013-22. PubMed ID: 9642078
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. 2. 4-(2-Malonyl)phenylalanine as a potent phosphotyrosyl mimetic.
Gao Y; Luo J; Yao ZJ; Guo R; Zou H; Kelley J; Voigt JH; Yang D; Burke TR
J Med Chem; 2000 Mar; 43(5):911-20. PubMed ID: 10715157
[TBL] [Abstract][Full Text] [Related]
18. Solution structure of the SH2 domain of Grb2 complexed with the Shc-derived phosphotyrosine-containing peptide.
Ogura K; Tsuchiya S; Terasawa H; Yuzawa S; Hatanaka H; Mandiyan V; Schlessinger J; Inagaki F
J Mol Biol; 1999 Jun; 289(3):439-45. PubMed ID: 10356320
[TBL] [Abstract][Full Text] [Related]
19. Dimer formation through domain swapping in the crystal structure of the Grb2-SH2-Ac-pYVNV complex.
Schiering N; Casale E; Caccia P; Giordano P; Battistini C
Biochemistry; 2000 Nov; 39(44):13376-82. PubMed ID: 11063574
[TBL] [Abstract][Full Text] [Related]
20. Grb2 SH2 domain-binding peptide analogs as potential anticancer agents.
Lung FD; Tsai JY
Biopolymers; 2003; 71(2):132-40. PubMed ID: 12767115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
